Drug Dosing During Intermittent Hemodialysis and Continuous Renal Replacement Therapy : Special Considerations in Pediatric Patients

Overview

Journal Paediatr Drugs

Specialties Pediatrics
Pharmacology

Date 2004 Feb 19

PMID 14969569

Citations 10

Authors

Michael A Veltri

Alicia M Neu

Barbara A Fivush

Rulan S Parekh

Susan L Furth

Affiliations

Soon will be listed here.

Abstract

Chronic renal failure is, fortunately, an unusual occurrence in children; however, many children with various underlying illnesses develop acute renal failure, and transiently require renal replacement therapy - peritoneal dialysis, intermittent hemodialysis (IHD), or continuous renal replacement therapy (CRRT). As children with acute and chronic renal failure often have multiple comorbid conditions requiring drug therapy, generalists, intensivists, nephrologists, and pharmacists need to be aware of the issues surrounding the management of drug therapy in pediatric patients undergoing renal replacement therapy. This article summarizes the pharmacokinetics and dosing of many drugs commonly prescribed for pediatric patients, and focuses on the management of drug therapy in pediatric patients undergoing IHD and CRRT in the intensive care unit setting. Peritoneal dialysis is not considered in this review. Finally, a summary table with recommended initial dosages for drugs commonly encountered in pediatric patients requiring IHD or CRRT is presented.

Citing Articles

Pharmacokinetic Research in Pediatric Extracorporeal Therapies: Current State and Future Directions.

Stitt G, Thibault C, Mueller B, Cies J, Daniel J, Arikan A Blood Purif. 2024; 53(6):520-526.

PMID: 39363977 PMC: 11449264. DOI: 10.1159/000534828.

Medication patterns and dosing guidance in pediatric patients supported with intermittent hemodialysis or continuous kidney replacement therapy.

McKnite A, Green D, Nelson R, Brewer S, Watt K Pediatr Nephrol. 2023; 39(5):1521-1532.

PMID: 38051389 PMC: 11332978. DOI: 10.1007/s00467-023-06199-z.

Cefepime Dosing in a Critically Ill Neonate Receiving Continuous Renal Replacement Therapy With the Cardio-Renal Pediatric Dialysis Emergency Machine (CARPEDIEM).

Toy C, Stimes G, Moore M, Srivaths P, Arikan A J Pediatr Pharmacol Ther. 2023; 28(2):167-171.

PMID: 37139247 PMC: 10150901. DOI: 10.5863/1551-6776-28.2.167.

Antimicrobial Dosing Recommendations in Pediatric Continuous Renal Replacement Therapy: A Critical Appraisal of Current Evidence.

Stitt G, Dubinsky S, Edginton A, Huang Y, Zuppa A, Watt K Front Pediatr. 2022; 10:889958.

PMID: 35633961 PMC: 9134108. DOI: 10.3389/fped.2022.889958.

Anti-infective Medicines Use in Children and Neonates With Pre-existing Kidney Dysfunction: A Systematic Review.

Minotti C, Barbieri E, Doni D, Impieri C, Giaquinto C, Dona D Front Pediatr. 2022; 10:868513.

PMID: 35558367 PMC: 9087830. DOI: 10.3389/fped.2022.868513.

References

Robert R, Rochard E, Malin F, Bouquet S . Amikacin pharmacokinetics during continuous veno-venous hemofiltration. Crit Care Med. 1991; 19(4):588-9. DOI: 10.1097/00003246-199104000-00029. View

Kearns G, Abdel-Rahman S, Blumer J, Reed M, James L, Jacobs R . Single dose pharmacokinetics of linezolid in infants and children. Pediatr Infect Dis J. 2001; 19(12):1178-84. DOI: 10.1097/00006454-200012000-00012. View

Leikin J, Shicker L, Orlowski J, Blair A, McAllister K . Hemodialysis removal of acyclovir. Vet Hum Toxicol. 1995; 37(3):233-4. View

Del Rio M, McCracken Jr G, Nelson J, Chrane D, Shelton S . Pharmacokinetics and cerebrospinal fluid bactericidal activity of ceftriaxone in the treatment of pediatric patients with bacterial meningitis. Antimicrob Agents Chemother. 1982; 22(4):622-7. PMC: 183803. DOI: 10.1128/AAC.22.4.622. View

Andrassy K . Pharmacokinetics of cefotaxime in dialysis patients. Diagn Microbiol Infect Dis. 1995; 22(1-2):85-7. DOI: 10.1016/0732-8893(95)00086-p. View

DAVIES S, Lacey L, Kox W, Brown E . Pharmacokinetics of cefuroxime and ceftazidime in patients with acute renal failure treated by continuous arteriovenous haemodialysis. Nephrol Dial Transplant. 1991; 6(12):971-6. DOI: 10.1093/ndt/6.12.971. View

Ward A, Richards D . Cefotetan. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1985; 30(5):382-426. DOI: 10.2165/00003495-198530050-00002. View

Regazzi M, Chirico G, Cristiani D, Rondini G, Rondanelli R . Cefoxitin in newborn infants. A clinical and pharmacokinetic study. Eur J Clin Pharmacol. 1983; 25(4):507-9. DOI: 10.1007/BF00542119. View

Keller E, Bohler J, Krumme B, Schollmeyer P . Single dose kinetics of piperacillin during continuous arteriovenous hemodialysis in intensive care patients. Clin Nephrol. 1995; 43 Suppl 1:S20-3. View

10.

Brunet S, LeBlanc M, Geadah D, Parent D, Courteau S, Cardinal J . Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. Am J Kidney Dis. 1999; 34(3):486-92. DOI: 10.1016/s0272-6386(99)70076-4. View

11.

Valtonen M, Tiula E, Backman J, Neuvonen P . Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother. 2000; 45(5):701-4. DOI: 10.1093/jac/45.5.701. View

12.

van der Werf T, Mulder P, Zijlstra J, Uges D, Stegeman C . Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH). Intensive Care Med. 1997; 23(8):873-7. DOI: 10.1007/s001340050424. View

13.

Schaad U, Stoeckel K . Single-dose pharmacokinetics of ceftriaxone in infants and young children. Antimicrob Agents Chemother. 1982; 21(2):248-53. PMC: 181867. DOI: 10.1128/AAC.21.2.248. View

14.

Kellum J, Mehta R, Angus D, Palevsky P, Ronco C . The first international consensus conference on continuous renal replacement therapy. Kidney Int. 2002; 62(5):1855-63. DOI: 10.1046/j.1523-1755.2002.00613.x. View

15.

ARMENDARIZ E, Chelluri L, Ptachcinski R . Pharmacokinetics of amikacin during continuous veno-venous hemofiltration. Crit Care Med. 1990; 18(6):675-6. DOI: 10.1097/00003246-199006000-00023. View

16.

Boulieu R, Bastien O, Gaillard S, Flamens C . Pharmacokinetics of acyclovir in patients undergoing continuous venovenous hemodialysis. Ther Drug Monit. 1998; 19(6):701-4. DOI: 10.1097/00007691-199712000-00016. View

17.

Cleary T, Pickering L, Kramer W, Culbert S, Frankel L, Kohl S . Amikacin pharmacokinetics in pediatric patients with malignancy. Antimicrob Agents Chemother. 1979; 16(6):829-32. PMC: 352961. DOI: 10.1128/AAC.16.6.829. View

18.

Konishi K, Suzuki H, Saruta T, Hayashi M, Deguchi N, Tazaki H . Removal of imipenem and cilastatin by hemodialysis in patients with end-stage renal failure. Antimicrob Agents Chemother. 1991; 35(8):1616-20. PMC: 245229. DOI: 10.1128/AAC.35.8.1616. View

19.

Manns M, SIGLER M, Teehan B . Continuous renal replacement therapies: an update. Am J Kidney Dis. 1998; 32(2):185-207. DOI: 10.1053/ajkd.1998.v32.pm9708602. View

20.

Armstrong D, Hidalgo H, Eldadah M . Vancomycin and tobramycin clearance in an infant during continuous hemofiltration. Ann Pharmacother. 1993; 27(2):224-7. DOI: 10.1177/106002809302700219. View